Imugene (ASX: IMU) - Discussing IMU's 2022 Biotech Opportunity

TL;DR

ImuGENE had a successful year in 2021 and has made significant progress in developing its core products, including B cells, oncolytic viruses, and oncolytics. The CEO, Leslie Chong, discusses the company's growth and future prospects.

Transcript

hey guys and welcome back to the asx investor channel and welcome to another ceo interview today we're going to be revisiting and really unpacking the story of eugene asximu had a breakout year in 2021 i'm sure you're all familiar with the story recently been included into the asx 200 benchmark index they've really progressed on a number of their d... Read More

Key Insights

• 🫰 ImuGENE had a breakout year in 2021, with significant growth and inclusion in the ASX 200 index.
• 🛀 The company's core products, including B cells, oncolytic viruses, and oncolytics, have shown promising developments in cancer treatment.
• 🪛 ImuGENE's growth has been driven by strategic decision-making and a focus on following the science.
• 😤 The company's leadership team's experience in clinical development and a robust patent portfolio contribute to its competitive advantage.
• 🥺 ImuGENE expects to have multiple partnership and collaboration opportunities in 2022, leading to commercial success and faster access to patients.
• 😃 Following the science opens up opportunities for collaboration with big pharmaceutical companies, expediting the development and marketing of ImuGENE's products.

Questions & Answers

Q: How has ImuGENE's growth evolved since Leslie Chong joined the company in 2015?

Leslie Chong joined ImuGENE in 2015 when the market cap was around $9 million. Since then, the company has experienced exponential growth, with its market cap now exceeding $3.5 billion. The growth has been strategic, focusing on developing products and acquiring molecules.

Q: What are ImuGENE's three main platforms, and how are they being utilized in cancer treatments?

ImuGENE's three main platforms are B cells, oncolytic viruses, and oncolytics. B cells are used as a cancer vaccine to target specific cancer cells, such as HER2-positive tumors. Oncolytic viruses, like VAccinia, are being tested in various solid tumors to attract T cells and enhance the immune response. Oncolytics is a combination therapy that works with cellular therapy drugs to treat solid tumors.

Q: What are the potential commercial outcomes for ImuGENE, such as partnerships, takeovers, or acquisitions?

ImuGENE is expecting to have multiple partnership and collaboration opportunities in 2022, particularly with the oncolytics platform. As the data matures and combinations are explored, the company expects to have meaningful conversations with potential partners. The PD1 backs platform is also drawing interest, and shareholders are likely to be excited about the partnership talks and collaborations in the coming year.

Q: What competitive advantages does ImuGENE have, apart from its technology?

ImuGENE's leadership team's experience in clinical development is a significant advantage. Their expertise allows the company to avoid repeating failures and make strategic decisions in trial designs and market targeting. Additionally, ImuGENE's extensive patent portfolio, with patents extending to 2037 and 2038, provides a strong competitive advantage, ensuring the company has market exclusivity for its products.

Summary & Key Takeaways

• ImuGENE experienced a breakout year in 2021 and was included in the ASX 200 benchmark index.

• The company's core products include B cells, oncolytic viruses, and oncolytics, which have all had significant developments in 2021 and are expected to continue making progress.

• ImuGENE's growth has been strategic and driven by a focus on developing meaningful cancer drugs for patients.